Bcl-2在肺癌中的表达及意义

Expression of Bcl-2 and its clinical significance in patients with lung cancer

目的探讨Bcl-2蛋白在肺癌中的表达与肺癌临床病理因素的关系。方法采用免疫组织化学方法,检测肺癌组织中Bcl-2蛋白表达的情况。结果在49例肺癌组织中,Bcl-2蛋白的阳性表达率是34.7%,显著高于对照组(12.5%)(P<0.05),在非小细胞肺癌组中随着病理分化程度不同,Bcl-2蛋白阳性表达呈显著性差异(P<0.01);在小细胞肺癌和非小细胞肺癌组Bcl-2蛋白表达也具有统计学差异(P<0.01)。结论 Bcl-2基因蛋白阳性表达率在小细胞肺癌组中显著高于非小细胞肺癌组,并可作为早期诊断肺癌的标志物。

Objective To explore the relationship between the expression of Bcl-2 and pathological factors in patients with lung cancer. Methods The expression of Bel-2 was detected by immunohistochemical ultrasensitive TM S-P method. Results The positive expression rate of Bcl-2 was 34. 7% in 49 lung cancer tissues, which was obviously higher than 12.5% in the controls （P 〈0.01 ）. With the different degrees of differentiation in the non-small cell lung cancer group, the positive expression of Bcl-2 showed statistical difference, and so did in the small cell lung cancer group （ P 〈 0. 01 ）. Conclusion The expression level of Bcl-2 was obviously higher in SCLC than in NSCLC （P 〈0. 01 ）, and it can be regarded as an important index in the early diagnosis of lung cancer.